Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations01:26

Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations

339
Renal calculi, commonly termed kidney stones, are crystalline solid masses that form in the kidneys but can occur at any point within the urinary system, encompassing the kidneys, ureters, bladder, and urethra.The pathophysiology of renal stones involves several key factors: supersaturation of the urine with stone-forming constituents, changes in urine pH, a decrease in urine volume, and the presence of substances that promote or inhibit stone formation.Supersaturation of Urine: This is the...
339
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

505
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
505
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

449
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
449
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

421
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
421
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

169
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
169
Nursing Assessment of the Genitourinary System I: Health History01:21

Nursing Assessment of the Genitourinary System I: Health History

338
The genitourinary system is critical to maintaining fluid balance, waste elimination, and reproductive function. Nurses play a vital role in assessing this system, beginning with a thorough health history. This process involves gathering patient information, identifying risk factors, and recognizing symptoms of genitourinary disorders. Early detection is vital for timely interventions and management.1. Gathering Patient InformationA complete health history includes the patient’s personal,...
338

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Nanoencapsulated Sirolimus plus Pegadricase: Results from the Randomized, Placebo-Controlled Phase 3 Trials.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Preservation and clonal behavior of extrachromosomal DNA in patient-derived xenograft models of childhood cancers.

Genome medicine·2026
Same author

A Manifold-Based Measure of Transcriptional Entropy for Quantifying Aging in Single Cells.

bioRxiv : the preprint server for biology·2026
Same author

Aging-induced hepatocyte CD44 drives IL6/STAT3 signaling and associates with impaired neighboring T cell function.

bioRxiv : the preprint server for biology·2026
Same author

Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapy.

Rheumatology (Oxford, England)·2025
Same author

Climate Change, Environmental Risk Factors, and Gout.

Arthritis care & research·2025

Related Experiment Video

Updated: Jan 4, 2026

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
10:02

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

Published on: October 3, 2020

4.3K

Asymptomatic hyperuricemia: is it really asymptomatic?

Kevin Yip1,2, Rebecca E Cohen1, Michael H Pillinger1,2

  • 1Department of Internal Medicine, Division of Rheumatology, New York University School of Medicine, New York, New York.

Current Opinion in Rheumatology
|November 6, 2019
PubMed
Summary

Asymptomatic hyperuricemia, high uric acid without gout, is linked to serious health issues like kidney disease and diabetes. More research is needed to confirm if lowering uric acid can prevent these conditions.

More Related Videos

Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography
03:19

Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography

Published on: June 21, 2024

2.0K
Synovial Fluid Analysis to Identify Osteoarthritis
07:51

Synovial Fluid Analysis to Identify Osteoarthritis

Published on: October 20, 2022

6.0K

Related Experiment Videos

Last Updated: Jan 4, 2026

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
10:02

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

Published on: October 3, 2020

4.3K
Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography
03:19

Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography

Published on: June 21, 2024

2.0K
Synovial Fluid Analysis to Identify Osteoarthritis
07:51

Synovial Fluid Analysis to Identify Osteoarthritis

Published on: October 20, 2022

6.0K

Area of Science:

  • Internal Medicine
  • Nephrology
  • Cardiology
  • Endocrinology

Background:

  • Hyperuricemia affects millions in the US, but its impact without gout symptoms remains unclear.
  • Asymptomatic hyperuricemia can lead to tissue crystal deposition and chronic inflammation.
  • It's associated with hypertension, kidney disease, heart disease, and diabetes, though studies have limitations.

Purpose of the Study:

  • To review the current understanding of asymptomatic hyperuricemia's role in comorbidities.
  • To evaluate evidence for urate-lowering treatment in asymptomatic hyperuricemia.

Main Methods:

  • Review of existing literature on asymptomatic hyperuricemia and associated conditions.
  • Analysis of treatment studies investigating urate-lowering therapies.

Main Results:

  • Asymptomatic hyperuricemia may contribute to comorbidities through inflammation and epigenetic changes.
  • Urate-lowering treatments show potential in reducing comorbidity risk, but studies are often small or flawed.
  • Evidence linking asymptomatic hyperuricemia to comorbidities is accumulating, but causality is not definitively established.

Conclusions:

  • Asymptomatic hyperuricemia appears to contribute to associated comorbidities.
  • Further prospective trials are essential to confirm causality and guide treatment decisions for urate-lowering therapy.